NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Mionaer1,

Progression Free Survival Slide.

13 placebo patients at risk 24 months from randomization.
5 events between 24 and 32 months from randomization.
8 placebo patients censored between 24 and 36 months from randomization.
0 placebo patients at risk 36 months from randomization.

NOTE:
5 placebo patients are censored between 0 and 12 months from randomization.
5 placebo patients are censored between 12 and 24 months from randomization.
8 placebo patients are censored between 24 and 36 months from randomization. Total: 18 placebo patients.

Placebo events: 81/99
81 - 64 crossover patients = 17 placebo patients/events. Most were too sick (remember RKmatter's nephew) to cross over or died before evidence of disease progression, IMO.
Remember original first endpoint:
Progression Free Survival (PFS): Time to objective demonstration of
disease progression or death in patients with no evidence of disease progression.
For more information about "censoring": see protocol (60 pages)